FDA recall record

Teva Pharmaceuticals USA IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for recall — FDA D-0765-2022

Presence of Particulate Matter: Product was found to contain silica and iron oxide

Class Iclassification
D-0765-2022official record ID
Apr 20, 2022report date

Recall record at a glance

Official recordD-0765-2022
CategoryDrug Recalls
ClassificationClass I
FDA record statusTerminated
Recalling firmTeva Pharmaceuticals USA Inc.
Report dateApr 20, 2022
Recall initiation dateMar 29, 2022
Quantity1565 vials
LocationParsippany, NJ, United States

Official product description

IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL Single Dose Vial, Rx Only, Teva Pharmaceuticals, USA, Inc., North Wales, PA 19454, NDC 0703-4154-11.

Why the product was recalled

Presence of Particulate Matter: Product was found to contain silica and iron oxide

Distribution information

Nationwide within the United States

How to read the classification

FDA Class I indicates a situation in which there is a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death. The classification shown here comes directly from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.

DrugApr 29, 2026

Claravis recall — FDA D-0521-2026

Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin

Class IIFDA: OngoingTeva Pharmaceuticals USA, Inc